Clinical Trial

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-01-13; most recent amendment 2026-04-06.
Status change: Recruiting → Active, Not Recruiting 2024-03-19
Trial Details
NCT Number NCT05696548
Lead Sponsor National Cancer Center Hospital East
Collaborators: Ono Pharmaceutical Co., Ltd.
Conditions Anaplastic Thyroid Cancer
Enrollment 51 participants
Start Date 2019-07-02
Primary Completion 2025-09-10 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-09